SHINE GROUP

READ

VIPER SHOCK

VIPER-SHOCK is a randomized, double-blind, clinical trial in 40 evaluable patients with septic shock investigating the effect of a plasma product (OCTAPLAS) vs. crystalloid as volume resuscitation during the acute phase.
Targeted Action Curing Trauma Induced Coagulopathy, is a 5-year research project, partly funded by the EC FP7 Program.

TACTIC

CONTACT

In case of interest or questions, please contact us on shine.group.copenhagen@gmail.com

About SHINE Group

The SHINE Group is based at the Capital Region Blood Bank, Rigshospitalet/Copenhagen University Hospital. Our mission is to improve the outcome of acute critically ill patients through translational research. One important focus is to decipher the pathophysiology responsible for development of multiorgan failure secondary to SHock INduced Endotheliopathy (SHINE). Another key area of our research concerns, patients with massive/complex bleeding conditions and how best to combat development of coagulopathy by improving goal-directed haemostatic resuscitation, entitled the Copenhagen Concept.

Our group encompass a management team, senior and junior researchers, laboratory facilities, students, and a clinical trial unit and teams of research assistants that are responsible for blood sampling and data collection in our clinical trials.

Clinical trials currently ongoing are:                                                                       Combat shock induced endotheliopathy in sepsis (COMBAT-SHINE), which is an adaptive phase 2B/3 RCT evaluating the safety and efficacy of low-dose prostacyclin infusion vs. placebo for 72 hours in 382 patients with septic SHINE.

Shock induced endotheliopathy in Trauma (SHINE-TRAUMA), which is a phase 2B RCT evaluating the safety and efficacy of low-dose prostacyclin infusion vs. placebo for 72 hours in 220 patients with traumatic SHINE.